Fibrosis: Clinical Trials

175 trials for Fibrosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

175 completed. 175 Phase 3, 34 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3175Completed 175
Phase 234Completed 34

Follow Fibrosis: new trials by email Literature Review of Fibrosis trials Research Report on Fibrosis

Trials (filtered) newest first · largest first

All 175 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis
Fecal microbiota transplantation - Liver Cirrhosis
Phase 3CompletedCristian Ichim192024-08-052026-03-27
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
Elafibranor, Placebo - Primary Biliary Cholangitis
Phase 3CompletedIpsen922024-07-092026-07-09
Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)
Seladelpar 10 mg, Placebo - Primary Biliary Cholangitis
Phase 3CompletedGilead Sciences962023-09-052026-06-04
LiveSMART Trial to Prevent Falls in Patients With Cirrhosis
Enhanced Usual Care, Lactulose, Investigator recommended exercise - Cirrhosis, Liver, Portal Hypertension
Phase 3CompletedUniversity of Michigan2332023-06-132026-07-31
A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia
OsrHSA, Plasbumin®-20 - Hypoalbuminemia, Hepatic Cirrhosis
Phase 3CompletedHealthgen Biotechnology Corp.3282023-04-102024-04-09
Lung Point of Care Ultrasound to Guide Albumin Administration in Cirrhosis
Lower albumin dosage - Cirrhosis, Cirrhosis Advanced
Phase 3CompletedCentro Medico Issemym722023-03-012025-07-18
Opioid Sparing Anesthesia in Patients With Liver Cirrhosis Undergoing Liver Resection
Opioid-based group (OB) (placebo/saline), Opioid sparing group (OS) (dexmedetomidine (PRECEDEX™ "dexmedetomidine hydrochloride" - Pfizer) and ketamine) - Liver Cirrhosis
Phase 3CompletedCairo University1002022-12-012023-08-08
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg, Placebo - Pulmonary Sarcoidosis
Phase 3CompletedaTyr Pharma, Inc.2682022-09-152026-06-04
Allopurinol and Quality of Life in Liver Cirrhosis
Allopurinol Tablet, Placebo - Cirrhosis, Liver
Phase 2 / Phase 3CompletedTanta University1002022-06-152023-10-31
Allopurinol to Prevent Cirrhosis Related Morbidities
Placebo, Allopurinol 300 MG - Cirrhosis
Phase 2 / Phase 3CompletedTanta University1002022-06-152026-11-04
Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis
Allopurinol 300 MG, Atorvastatin 20mg, Placebo - Cirrhosis, Hepatic Encephalopathy
Phase 2 / Phase 3CompletedTanta University1652022-06-152026-11-17
Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19
Longidaza®, Placebo - Post-Acute COVID-19 Syndrome, Lung Disease With Polymyositis
Phase 3CompletedNPO Petrovax3922022-04-082025-06-03
Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis
Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo - Primary Biliary Cholangitis
Phase 2 / Phase 3CompletedZydus Therapeutics Inc.1962022-04-012026-09-17
Growth Hormone in Decompensated Liver Cirrhosis
Growth Hormone - Liver Cirrhosis, Fibrosis
Phase 2 / Phase 3CompletedPost Graduate Institute of Medical Education and Research, Chandigarh962022-02-012025-12-16
Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital
cyclosporine - COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Phase 3CompletedAlexandria University662022-01-032025-05-14
Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.
Hydronidone capsules, The placebo capsules - Liver Fibrosis
Phase 3CompletedBeijing Continent Pharmaceutical Co, Ltd.2482021-12-302024-12-20
A Trial to Improve Quality of Life in People With Cirrhosis
Lactulose - Cirrhosis
Phase 2 / Phase 3CompletedUniversity of Michigan562021-11-102023-11-21
Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis
Obeticholic Acid Tablets(OCA), UDCA, Placebo - Primary Biliary Cholangitis
Phase 3CompletedNanjing Chia-tai Tianqing Pharmaceutical1082021-09-232024-07-11
Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)
Linerixibat, Placebo - Pruritus
Phase 3CompletedGlaxoSmithKline2382021-08-272026-07-22
RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Seladelpar 10 mg, Placebo, Seladelpar 5 mg - Primary Biliary Cholangitis
Phase 3CompletedGilead Sciences1932021-04-212024-09-05

Showing 20 of 175. Sign in to see all of them.

Narrower conditions

Liver Cirrhosis (47)  ·  Hepatitis C (32)  ·  Hepatitis C, Chronic (23)  ·  Ascites (17)  ·  Liver Cirrhosis, Biliary (17)  ·  Pulmonary Fibrosis (16)  ·  Hypertension, Portal (11)  ·  Cicatrix (9)  ·  Idiopathic Pulmonary Fibrosis (8)  ·  Esophageal and Gastric Varices (7)  ·  Cicatrix, Hypertrophic (6)  ·  Liver Diseases (6)  ·  Lung Diseases (6)  ·  Lung Diseases, Interstitial (6)

Broader conditions

Pathological Conditions, Signs and Symptoms (175)  ·  Pathologic Processes (171)  ·  Digestive System Diseases (112)  ·  Liver Diseases (104)  ·  Infections (47)  ·  Virus Diseases (43)  ·  Blood-Borne Infections (42)  ·  Communicable Diseases (42)  ·  Hepatitis (42)  ·  Hepatitis, Viral, Human (41)  ·  RNA Virus Infections (41)  ·  Flaviviridae Infections (39)  ·  Disease Attributes (28)  ·  Chronic Disease (26)

Interventions

Ribavirin (18)  ·  Tolvaptan (8)  ·  Sofosbuvir (6)  ·  dasabuvir (6)  ·  ombitasvir (6)  ·  paritaprevir (6)  ·  peginterferon alfa-2b (6)  ·  Terlipressin (5)  ·  sofosbuvir-velpatasvir drug combination (5)  ·  Acetylcysteine (4)  ·  Granulocyte Colony-Stimulating Factor (4)  ·  glecaprevir and pibrentasvir (4)  ·  peginterferon alfa-2a (4)  ·  pirfenidone (4)  ·  Allopurinol (3)

Sponsors

AbbVie (10)  ·  Gilead Sciences (8)  ·  Assistance Publique - Hôpitaux de Paris (7)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (7)  ·  Merck Sharp & Dohme LLC (5)  ·  Post Graduate Institute of Medical Education and Research, Chandigarh (5)  ·  Genentech, Inc. (3)  ·  Hospital Clinic of Barcelona (3)  ·  Otsuka Pharmaceutical Co., Ltd. (3)  ·  Tanta University (3)  ·  Bambino Gesù Hospital and Research Institute (2)  ·  Boehringer Ingelheim (2)  ·  Catalysis SL (2)  ·  Duke University (2)  ·  GlaxoSmithKline (2)

Countries

United States (57)  ·  France (32)  ·  United Kingdom (26)  ·  Spain (25)  ·  Germany (24)  ·  Canada (23)  ·  Italy (21)  ·  China (16)  ·  Belgium (14)  ·  Russia (12)  ·  Japan (11)  ·  Australia (10)  ·  Israel (10)  ·  Poland (10)  ·  India (9)

Top investigators

Imre Noth, MD (3)  ·  Eric Cohen, MD (2)  ·  Fernando Martinez, MD (2)  ·  Ganesh Raghu, MD (2)  ·  James Loyd, MD (2)  ·  Jay Ryu, MD (2)  ·  Jesse Roman, MD (2)  ·  Joe Lasky, MD (2)  ·  John McNally, PhD (2)

Results publications

PMID 27847279, PMID 28388260, PMID 26835133, PMID 35688625, PMID 36740893, PMID 37391667, PMID 17105757, PMID 21571362, PMID 22027579, PMID 24834811, PMID 24836310, PMID 25151571, PMID 25890798, PMID 26111071, PMID 26400368, PMID 26575258, PMID 26968970, PMID 27672117, PMID 27708114, PMID 28039616, PMID 28526798, PMID 30072107, PMID 30116539, PMID 30176872, PMID 30472023, PMID 30729456, PMID 30971229, PMID 31047956, PMID 31153107, PMID 31401786, PMID 31914963, PMID 32217654, PMID 33239000, PMID 33434107, PMID 33902584, PMID 37467180, PMID 42548365, PMID 10077078, PMID 11242330, PMID 11348456, PMID 12845617, PMID 16306520, PMID 16306522, PMID 16790698, PMID 17058231, PMID 17133492, PMID 17206944, PMID 17560680, PMID 17717203, PMID 17901414

NIH funding

2014 (6), 2016 (3), 2005 (2), 2009 (2), U10HL080413 (2), 2004 (1), 2019 (1), 2023 (1), R01DK046580 (1), R01DK046602 (1), R01DK051523 (1), R03DK055618 (1), U01HL060839 (1), U24HL145265 (1)